



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

TAT (m7): 293T Lysate: sc-123923

BACKGROUND

TAT (tyrosine aminotransferase) is a 454 amino acid protein that localizes to mitochondria and belongs to the class-I pyridoxal-phosphate-dependent aminotransferase family. Existing as a homodimer, TAT uses pyridoxal phosphate as a cofactor to catalyze the conversion of L-tyrosine into p-hydroxyphenyl-pyruvate, a reaction that is important in amino acid degradation. Defects in the gene encoding TAT are the cause of tyrosinemia type 2 (TYRO2), an inborn error of metabolism that is associated with elevated levels of tyrosine in blood and urine and is characterized by palmoplantar keratosis, painful corneal ulcers and mental retardation. The gene encoding TAT maps to human chromosome 16, which encodes over 900 genes and comprises nearly 3% of the human genome.

REFERENCES

- Andersson, S.M. 1982. Induction of cytosolic tyrosine aminotransferase by dexamethasone in organ culture of fetal human liver. *Early Hum. Dev.* 6: 165-169.
- Rettenmeier, R., Natt, E., Zentgraf, H. and Scherer, G. 1990. Isolation and characterization of the human tyrosine aminotransferase gene. *Nucleic Acids Res.* 18: 3853-3861.
- Natt, E., Kida, K., Odievre, M., Di Rocco, M. and Scherer, G. 1992. Point mutations in the tyrosine aminotransferase gene in tyrosinemia type II. *Proc. Natl. Acad. Sci. USA* 89: 9297-9301.
- Hühn, R., Stoermer, H., Klingele, B., Bausch, E., Fois, A., Farnetani, M., Di Rocco, M., Boue, J., Kirk, J.M., Coleman, R. and Scherer, G. 1998. Novel and recurrent tyrosine aminotransferase gene mutations in tyrosinemia type II. *Hum. Genet.* 102: 305-313.
- Rehman, K.K., Ayesha, Q., Khan, A.A., Ahmed, N. and Habibullah, C.M. 2004. Tyrosine aminotransferase and γ -glutamyl transferase activity in human fetal hepatocyte primary cultures under proliferative conditions. *Cell Biochem. Funct.* 22: 89-96.
- Online Mendelian Inheritance in Man, OMIM[™]. 2005. Johns Hopkins University, Baltimore, MD. MIM Number: 276600. World Wide Web URL: <http://www.ncbi.nlm.nih.gov/omim/>
- Maydan, G., Andresen, B.S., Madsen, P.P., Zeigler, M., Raas-Rothschild, A., Zlotogorski, A., Gutman, A. and Korman, S.H. 2006. TAT gene mutation analysis in three Palestinian kindreds with oculocutaneous tyrosinaemia type II; characterization of a silent exonic transversion that causes complete missplicing by exon 11 skipping. *J. Inher. Metab. Dis.* 29: 620-626.
- Charfeddine, C., Monastiri, K., Mokni, M., Laadjimi, A., Kaabachi, N., Perin, O., Nilges, M., Kassas, S., Keirallah, M., Guediche, M.N., Kamoun, M.R., Tebib, N., Ben Dridi, M.F., Boubaker, S., Ben Osman, A. and Abdelhak, S. 2006. Clinical and mutational investigations of tyrosinemia type II in Northern Tunisia: identification and structural characterization of two novel TAT mutations. *Mol. Genet. Metab.* 88: 184-191.
- Pasternack, S.M., Betz, R.C., Brandrup, F., Gade, E.F., Clemmensen, O., Lund, A.M., Christensen, E. and Bygum, A. 2009. Identification of two new mutations in the TAT gene in a Danish family with tyrosinaemia type II. *Br. J. Dermatol.* 160: 704-706.

CHROMOSOMAL LOCATION

Genetic locus: Tat (mouse) mapping to 8 D3.

PRODUCT

TAT (m7): 293T Lysate represents a lysate of mouse TAT transfected 293T cells and is provided as 100 μ g protein in 200 μ l SDS-PAGE buffer.

APPLICATIONS

TAT (m7): 293T Lysate is suitable as a Western Blotting positive control for mouse reactive TAT antibodies. Recommended use: 10-20 μ l per lane.


Control 293T Lysate: sc-117752 is available as a Western Blotting negative control lysate derived from non-transfected 293T cells.

TAT (A-6): sc-374065 is recommended as a positive control antibody for Western Blot analysis of enhanced mouse TAT expression in TAT transfected 293T cells (starting dilution 1:100, dilution range 1:100-1:1,000).


RECOMMENDED SUPPORT REAGENTS

To ensure optimal results, the following support reagents are recommended: 1) Western Blotting: use m-IgG κ BP-HRP: sc-516102 or m-IgG κ BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz Marker[™] Molecular Weight Standards: sc-2035, UltraCruz[®] Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048.

DATA



TAT (A-6): sc-374065. Western blot analysis of TAT expression in non-transfected: sc-117752 (A) and mouse TAT transfected: sc-123923 (B) 293T whole cell lysates.



TAT (D-9): sc-365512. Western blot analysis of TAT expression in non-transfected: sc-117752 (A) and mouse TAT transfected: sc-123923 (B) 293T whole cell lysates.

STORAGE

Store at -20° C. Repeated freezing and thawing should be minimized. Sample vial should be boiled once prior to use. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.